Suzaki Isao, Kimura Yurika, Tanaka Akihiko, Hirano Kojiro, Ishibashi Atsushi, Mizuyoshi Tomomi, Ando Izumi, Kitajima Tatsuya, Watanabe So, Hinohira Yasuyuki, Kobayashi Hitome
Department of Otorhinolaryngology, School of Medicine, Showa University, Tokyo, Japan.
Department of Otorhinolaryngology, School of Medicine, Showa University, Tokyo, Japan; Tokyo Metropolitan Health and Medical Treatment Corporation, Ebara Hospital, Tokyo, Japan.
Auris Nasus Larynx. 2019 Feb;46(1):141-146. doi: 10.1016/j.anl.2018.05.007. Epub 2018 Jun 13.
Eosinophilic otitis media (EOM), which is characterized by the accumulation of eosinophils in middle ear effusion and the middle ear mucosa, is a refractory type of otitis media that is often associated with asthma. Although an early diagnosis and appropriate treatment are necessary to prevent the progression of hearing loss in patients with EOM, there are currently no well-established treatments for this condition. We treated a 60-year-old male patient with asthma and EOM. The patient's asthma was poorly controlled, despite the use of high-dose inhaled corticosteroids, long-acting beta-agonist treatment, and the regular use of systemic corticosteroids. Mepolizumab, an anti-IL-5 monoclonal antibody, was started to treat the patient's refractory asthma. At 4 months after the initiation of mepolizumab treatment, the patient's asthma, hearing, and middle ear effusion improved. The present case suggests that mepolizumab therapy can control EOM and asthma.
嗜酸性粒细胞性中耳炎（EOM）的特征是中耳积液和中耳黏膜中嗜酸性粒细胞积聚，是一种难治性中耳炎，常与哮喘相关。尽管早期诊断和适当治疗对于预防EOM患者听力损失的进展是必要的，但目前尚无针对这种疾病的成熟治疗方法。我们治疗了一名患有哮喘和EOM的60岁男性患者。尽管使用了高剂量吸入性糖皮质激素、长效β受体激动剂治疗以及定期使用全身性糖皮质激素，该患者的哮喘仍控制不佳。美泊利珠单抗，一种抗IL-5单克隆抗体，开始用于治疗该患者的难治性哮喘。在美泊利珠单抗治疗开始4个月后，患者的哮喘、听力和中耳积液均有所改善。本病例表明美泊利珠单抗治疗可控制EOM和哮喘。
